The Infectious Diseases Society of America (IDSA) has updated the following recommendation section based on newly available literature and/or approvals. These updates will be integrated into the website soon:
- Molnupiravir: New recommendation on the use of molnupiravir for ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease who have no other treatment options
- Remdesivir: New recommendation on the use of remdesivir for ambulatory patients
- Neutralizing Antibodies for Prophylaxis: New recommendation on the use of tixagevimab/cilgavimab for pre-exposure prophylaxis in adults at increased risk for inadequate immune response to COVID-19 vaccine or for whom COVID-19 vaccine is not recommended
- Oral Antivirals (NEW): New recommendation on the use of nirmatrelvir/ritonavir in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease
